Related Experiment Videos
Enzyme replacement therapy in Fabry disease: clinical implications.
Frank Breunig1, Anita Knoll, Christoph Wanner
1Department of Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany. Breuning_f@klinik.uni-wuerzburg.de
Current Opinion in Nephrology and Hypertension
|August 16, 2003
Summary
Enzyme replacement therapy effectively clears substrate storage in Fabry disease, a genetic disorder. While promising for symptom stabilization, long-term outcomes in severe cases require further study.
Area of Science:
- Genetics and rare diseases
- Lysosomal storage disorders
- Biochemistry
Background:
- Fabry disease is an X-linked lysosomal storage disorder due to alpha-galactosidase A deficiency.
- Intracellular glycosphingolipid accumulation, primarily globotriaosylceramide, causes progressive organ damage.
- Key affected systems include the vasculature, heart, brain, and kidneys, potentially leading to end-stage renal disease.
Purpose of the Study:
- To provide a current overview of therapeutic advances in Fabry disease.
- To discuss future directions in managing this condition.
Main Methods:
- Review of current literature on Fabry disease therapies.
- Analysis of clinical trial data for enzyme replacement therapy (ERT).
- Exploration of emerging treatment strategies like enzyme enhancement and gene therapy.
Main Results:
- Enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A is the sole specific treatment.
- ERT has demonstrated safety and efficacy in reducing substrate storage and stabilizing symptoms, including kidney function.
- Pharmacological chaperones offer an alternative for patients with residual enzyme activity, and gene therapy is a future possibility.
Conclusions:
- Significant progress has been achieved with ERT for Fabry disease patients.
- While ERT effectively clears substrate deposits, long-term clinical outcome data in patients with severe organ involvement remain limited.